eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
The mass spectrometry phosphoproteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD018873. Immunoblotting raw data have been deposited to Mendeley Data repository with the following https://doi.org/10.17632/xjsdxnpxkb.1
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:dnet:digitalcsic_::3df8ff162d1e1b2f52fa4cf15f1a350f |
| Acceso en línea: | http://hdl.handle.net/10261/426073 https://api.elsevier.com/content/abstract/scopus_id/85132535531 |
| Access Level: | acceso abierto |
| Palabra clave: | AML Biomarkers Cancer Combination therapy eEF2K Kinase activity Phosphoproteomics Synergy |
| Sumario: | The mass spectrometry phosphoproteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD018873. Immunoblotting raw data have been deposited to Mendeley Data repository with the following https://doi.org/10.17632/xjsdxnpxkb.1 |
|---|